Search Results for:

Hikma and Celltrion Announce Collaboration to Market Adalimumab Biosimilar YUFLYMA in Middle East and North Africa

On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa.  CT-P17 is a high-concentration, low-volume and citrate-free adalimumab biosimilar, indicated for the treatment of a number of conditions including rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease.  According to Hikma, CT-P17 provides…

Read More

Q1 2022 Earnings Roundup: Biologics and Biosimilars Update

Below are some highlights from first quarter 2022 earnings reports recently released by biologics and biosimilars companies: Biogen:  Last week, Biogen reported total quarterly revenues of $2,532 million, and biosimilar revenue of $194 million decreased 5% versus the prior year.  As reflected by the assumption in the Company’s Full Year…

Read More

Alvotech and AbbVie Resolve Disputes Relating to Alvotech’s Adalimumab Biosimilar in Europe

Alvotech Holdings S.A. (“Alvotech”) announced today that it has resolved all intellectual property disputes with AbbVie in Europe related to Alvotech’s AVT02 (adalimumab) biosimilar candidate.  This announcement follows Alvotech’s announcement last month that the company had settled its pending disputes related to AVT02 with AbbVie in the U.S., and states…

Read More

Biosimilar Cyltezo® shows similar clinical outcomes to Humira® in treatment of moderate-to-severe chronic plaque psoriaris

Boehringer Ingelheim announced earlier this week that results from a phase III study showed that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in the treatment of people with moderate-to-severe chronic plaque psoriasis. The results support Boehringer Ingelheim’s supplemental biologics application to designate Cyltezo® as an interchangeable…

Read More